- Home
- OTLK vs SHMD Comparison
OTLK vs SHMD Comparison
Compare OTLK & SHMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OTLK | SHMD |
|---|---|---|
| Founded | 2010 | 1864 |
| Country | United States | Germany |
| Employees | N/A | 734 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.6M | 279.8M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | OTLK | SHMD |
|---|---|---|
| Price | $1.02 | $4.72 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 13.4M | 458.4K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,146,123.00 | N/A |
| Revenue This Year | $1,430.98 | N/A |
| Revenue Next Year | $173.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $2.00 |
| 52 Week High | $3.39 | $10.65 |
Technical Indicators
Market Signals| Indicator | OTLK | SHMD |
|---|---|---|
| Relative Strength Index (RSI) | 41.12 | 46.62 |
| Support Level | $0.75 | $3.81 |
| Resistance Level | $1.83 | $7.36 |
| Average True Range (ATR) | 0.18 | 0.34 |
| MACD | -0.04 | 0.10 |
| Stochastic Oscillator | 18.48 | 75.68 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).